


Intrinseque Health Establishes Wholly Foreign-Owned Enterprise in Shanghai Free Trade Zone, China

SHANGHAI, CHINA, June 30, 2025 /EINPresswire.com/ -- Intrinseque Health is proud to announce the official establishment of its wholly foreign-owned enterprise (WFOE) in the China (Shanghai) Pilot Free Trade Zone. The newly registered entity, Intrinseque Health Technology (Shanghai) Co., Ltd., represents a significant step in the company's strategic expansion into the <u>clinical</u> <u>supply chain</u> and healthcare services market.

With a registered capital of USD 1 million, this expansion reflects Intrinseque Health's commitment to enhancing its presence in Asia and



strengthening its operational capabilities in one of the most dynamic and rapidly growing markets in the world.

Mr. Nitin Jain, stated, "Our launch in China underscores our dedication to providing streamlined,

٢

We Build & Execute Complex Clinical Supply Plans" Intrinseque Health compliant, and regionally tailored clinical supply chain solutions across Asia. Shanghai's Free Trade Zone offers an ideal environment to drive innovation and efficiency in our service delivery."

Located at Room 2601-A, No. 161, Lujiazui East Road,

Shanghai, the new entity will enable Intrinseque Health to better serve its local and global pharmaceutical, biotech, and clinical research partners by delivering enhanced logistical, regulatory, and project management support from within China.

This development follows the company's earlier regional expansions and aligns with its long-

term strategy to build a robust global footprint in clinical supply chain management.

About Intrinseque Health

Intrinseque Health is an EN ISO 13485, ISO 9001 and GDPMDS certified global clinical development support organisation, accomplished in facilitating the development of clinical trial studies globally. Around the globe, Intrinseque Health has offices in countries like the United States (Delaware), The Netherlands (Amsterdam), United Kingdom (London), China (Beijing), Taiwan (Taipei) & Korea (Seoul), India (Delhi) and Singapore. Being managed by drug development professionals with over 300 years of combined experience supporting global clinical trials across various therapeutic areas, the team at Intrinseque Health knows and understands the needs of the clients while providing best-in-class solutions to overcome the hurdles and pain points of conducting a clinical trial.

Intrinseque Health is the industry expert in solving clinical supply chain challenges, such as product availability & lead times, selection of in-country sourcing Vs. import, import regulations and IOR/EOR requirements, storage & warehousing, kitting, labelling & printing, installation, calibration, validation, servicing & maintenance of equipment and supplies, local sourcing, and procurement services, all while maintaining the highest levels of quality throughout study timelines. Intrinseque Health engages early with its clients and utilises an operational methodology based on a proven, cost-effective clinical supply chain strategy for each clinical trial. It firmly believes that even the most minor and essential items, irrespective of their utility, should be there every time because nothing is more important than the value of patients' life. Intrinseque Health aims to become the global leader in clinical trial support services and constantly thrives in innovating and offering unique solutions.

Prajjwal Sharma Intrinseque Health contact@intrinsequehealth.com Visit us on social media: LinkedIn Facebook YouTube X

This press release can be viewed online at: https://www.einpresswire.com/article/826927944

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire[™], tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information. © 1995-2025 Newsmatics Inc. All Right Reserved.